*Department of Psychiatry, Center for Health Outcomes and Interdisciplinary Research, Massachusetts General Hospital, Boston, Massachusetts
†Harvard Medical School, Boston, Massachusetts
‡Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland
Associate Editor Victor W. Henderson oversaw the review process for this article.
Supported in part by a federal R01 research grant (W81XWH-17-1-0121) from the Department of Defense to A.-M.V.
A.-M.V. receives funding from the National Institutes of Health and serves on the scientific advisory board for the Calm application. E.G.L. receives funding from the Children’s Tumor Foundation, Neurofibromatosis Northeast, Neurofibromatosis Midwest, and Texas Neurofibromatosis Foundations. The remaining authors declare no conflicts of interest.
Correspondence: Ana-Maria Vranceanu, PhD, Department of Psychiatry, Center for Health Outcomes and Interdisciplinary Research, Massachusetts General Hospital, One Bowdoin Square, 1st floor, Suite 100, Boston, Massachusetts 02114 (email: [email protected]).
Supplemental digital content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.cogbehavneurol.com.
